Markets open

BeOne Medicines Ltd. American Depositary Shares

ONC · NASDAQ-GS

Jun 2026upcoming

Next quarter

Consensus is $1.40 EPS for Jun 2026 across 1 estimates, ranging $1.40 to $1.40.

ONC Mar 2026

Reported May 6, 2026

Beat 168.49%

EPS estimate: $0.73
EPS actual: $1.96
Revenue estimate: —
Revenue actual: —
1-day move: +1.17%

Call highlights have not been generated for this quarter.

Symbol: ONC
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Caribbean
Exchange: NASDAQ-GS

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

Key Issues

Bullish view

Revenue increased from $3.8 billion in FY2024 to $5.3 billion in FY2025, while net income improved from a $0.6 billion loss to $0.3 billion of profit, supporting a case for continuing operating momentum.

Bearish view

The evidence covers only one year of improvement and does not establish whether the revenue growth or return to profitability is durable.

Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Analyst Consensus

See all

Buy

0 analysts

$329

Current

—

Low

$412

Average

—

High

Average target implies +25.08% versus the current price.

Earnings History

BeatMissNo estimate

BeOne Medicines Ltd. American Depositary Shares

Next quarter

Peers